NASDAQ:MBIO - Nasdaq - US62818Q3020 - Common Stock - Currency: USD
1.17
+0.01 (+0.86%)
The current stock price of MBIO is 1.17 USD. In the past month the price decreased by -6.4%. In the past year, price decreased by -92.64%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.84 | 342.32B | ||
AMGN | AMGEN INC | 14.56 | 155.14B | ||
GILD | GILEAD SCIENCES INC | 13.46 | 129.91B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1736.21 | 129.44B | ||
REGN | REGENERON PHARMACEUTICALS | 12.47 | 62.19B | ||
ARGX | ARGENX SE - ADR | 331.32 | 38.44B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.46B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.92B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.00B | ||
NTRA | NATERA INC | N/A | 20.94B | ||
BIIB | BIOGEN INC | 7.3 | 17.59B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.42B |
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company is headquartered in Worcester Massachusetts, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2017-08-22. The firm has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. The company is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. The company has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors.
MUSTANG BIO INC
377 Plantation Street
Worcester Massachusetts MASSACHUSETTS 01605 US
CEO: Manuel Litchman
Employees: 80
Company Website: https://www.mustangbio.com/
Investor Relations: https://ir.mustangbio.com/
Phone: 17816524500
The current stock price of MBIO is 1.17 USD. The price increased by 0.86% in the last trading session.
The exchange symbol of MUSTANG BIO INC is MBIO and it is listed on the Nasdaq exchange.
MBIO stock is listed on the Nasdaq exchange.
MUSTANG BIO INC (MBIO) has a market capitalization of 3.87M USD. This makes MBIO a Nano Cap stock.
MUSTANG BIO INC (MBIO) currently has 80 employees.
MUSTANG BIO INC (MBIO) has a resistance level at 1.3. Check the full technical report for a detailed analysis of MBIO support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
MBIO does not pay a dividend.
MUSTANG BIO INC (MBIO) will report earnings on 2025-05-13.
MUSTANG BIO INC (MBIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.32).
The outstanding short interest for MUSTANG BIO INC (MBIO) is 2.83% of its float. Check the ownership tab for more information on the MBIO short interest.
ChartMill assigns a fundamental rating of 1 / 10 to MBIO. Both the profitability and financial health of MBIO have multiple concerns.
Over the last trailing twelve months MBIO reported a non-GAAP Earnings per Share(EPS) of -6.32. The EPS increased by 43.82% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -169.23% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 83% to MBIO. The Buy consensus is the average rating of analysts ratings from 7 analysts.